BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsumoto T, Tsuchiya T, Hirano T, Laurent T, Matsunaga K, Takata J. Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database. Clinicoecon Outcomes Res 2021;13:145-53. [PMID: 33658813 DOI: 10.2147/CEOR.S293698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Eto T, Karasuyama Y, González V, Del Campo García A. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers. Cancer Chemother Pharmacol 2021;88:713-22. [PMID: 34269848 DOI: 10.1007/s00280-021-04324-z] [Reference Citation Analysis]